仁度生物(688193) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥70,433,694.06, a decrease of 15.57% compared to the same period last year[5] - The net profit attributable to shareholders was ¥1,833,062.99, down 89.92% year-on-year, while the net profit after deducting non-recurring gains and losses was a loss of ¥4,661,307.85, a decrease of 127.80%[5] - The company reported a basic earnings per share of ¥0.08, down 86.89% compared to the same period last year[6] - Total operating revenue for the first three quarters of 2022 reached ¥240,095,689.86, an increase of 7.3% compared to ¥223,558,205.60 in the same period of 2021[20] - Net profit for the first three quarters of 2022 was ¥23,754,699.23, a decrease of 53.7% compared to ¥51,221,003.23 in the same period of 2021[21] - The total comprehensive income attributable to the parent company for Q3 2022 was CNY 24,596,836, a decrease from CNY 51,183,075 in Q3 2021, representing a decline of approximately 52%[22] - Basic earnings per share for Q3 2022 were CNY 0.71, down from CNY 1.71 in Q3 2021, reflecting a decrease of about 58%[22] Expenses and Costs - Research and development expenses totaled ¥11,411,247.87, an increase of 55.49% year-on-year, accounting for 16.20% of operating revenue, up 7.40 percentage points[6] - Total operating costs for the first three quarters of 2022 were ¥220,908,652.51, up 31.9% from ¥167,482,998.67 in the previous year[20] - Research and development expenses for the first three quarters of 2022 amounted to ¥26,085,664.60, an increase of 44.3% from ¥18,077,334.81 in the previous year[20] - The company’s financial expenses showed a net income of -¥2,969,612.75, compared to -¥1,288,575.20 in the previous year, indicating a worsening financial position[20] Assets and Liabilities - Total assets reached ¥1,086,541,740.11, representing a year-on-year increase of 186.98%[6] - Total liabilities as of the end of Q3 2022 were ¥120,260,478.88, compared to ¥90,860,601.43 at the end of Q3 2021, reflecting a year-over-year increase of 32.4%[19] - The company’s total current assets were reported at ¥975,116,140.92, compared to ¥282,537,896.95 in the previous year, showing a growth of approximately 245%[17] - The company’s total current liabilities increased to ¥91,879,525.49, compared to ¥66,306,799.11 in the previous year, marking a rise of 38.7%[19] - Total equity attributable to shareholders reached ¥966,281,261.23, significantly up from ¥287,747,428.24 in the same period last year[19] Cash Flow - Cash flow from operating activities was negative at -¥15,431,886.63, a decrease of 169.25%[6] - Net cash flow from operating activities for the first three quarters of 2022 was negative CNY 15,431,886.63, compared to positive CNY 22,284,045.82 in the same period of 2021[23] - Cash inflow from investment activities in the first three quarters of 2022 was CNY 744,498,273.44, significantly higher than CNY 23,340,056.29 in the same period of 2021[23] - The net cash flow from investment activities for the first three quarters of 2022 was negative CNY 110,972,110.31, compared to negative CNY 14,398,788.51 in the same period of 2021[23] - Cash inflow from financing activities for the first three quarters of 2022 was CNY 675,692,000, compared to CNY 3,000,000 in the same period of 2021[23] - The net increase in cash and cash equivalents for the first three quarters of 2022 was CNY 526,725,061.46, compared to CNY 5,174,896.68 in the same period of 2021[23] - The ending balance of cash and cash equivalents as of the end of Q3 2022 was CNY 723,992,494.80, up from CNY 176,775,609.59 at the end of Q3 2021[23] - The company reported a significant increase in cash received from investment recoveries, totaling CNY 737,110,730.59 in the first three quarters of 2022, compared to CNY 22,000,000 in the same period of 2021[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,481[12] - The report indicates that there are no significant changes in the shareholder structure or related party transactions that could impact the company's operations[15] Other Information - The company has not disclosed any new product launches or technological advancements during this quarter[15] - There were no significant mergers or acquisitions reported in the third quarter of 2022[15] - The company has not provided specific future guidance or market expansion strategies in the current report[15] - The company has not executed any mergers or acquisitions during the reporting period, with no net profit reported from merged entities[22]